Healthcare >> Analyst Interviews >> May 3, 2004
DAVID WOOD is a Senior Biotechnology Analyst at Rodman & Renshaw. Prior
to joining Rodman, Dr. Wood was an Analyst in the equity research
department of Stephens Inc. He earned his PhD in Molecular Oncology and
Immunology, studying the molecular mechanism of chemotherapy-induced
apoptosis of leukemia cells. In addition, Dr. Wood carried out
postdoctoral training at Children's Hospital/Harvard Medical School,
studying gene expression in Alzheimer's disease. He earned his PhD from
New York University School of Medicine and his BA in Biology from
Bowdoin College Profile
Rodman & Renshaw?
Dr. Wood: My coverage list right now consists of Dyax (DYAX), GTC
Biotherapeutics (GTCB), Nuvelo
